Core Viewpoint - NuCana plc has appointed Theresa Bruce as Chief Operating Officer, effective January 1, 2026, to enhance its leadership team and advance its clinical pipeline focused on cancer treatment [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company dedicated to improving cancer treatment outcomes through its ProTide technology, which aims to transform conventional chemotherapy agents into more effective and safer medicines [3]. - The company’s pipeline includes NUC-7738, a novel anti-cancer agent currently in a Phase 1/2 study, and NUC-3373, derived from the widely used chemotherapy agent 5-fluorouracil [3]. Leadership Appointment - Theresa Bruce brings over 25 years of experience in oncology research and development, having held senior leadership roles in various biotechnology companies and clinical research organizations [2]. - Her operational leadership is expected to be crucial for advancing NuCana's pipeline, particularly for NUC-7738 and NUC-3373, and for preparing registration strategies for potential marketing approvals [2]. Strategic Focus - The company aims to generate data in 2026 from the Phase 1/2 expansion study of NUC-7738 in combination with pembrolizumab for melanoma patients [2]. - NuCana anticipates a cash runway extending into 2029, which will support its ongoing clinical studies and development efforts [2].

Core Insights - NuCana plc presented new clinical data for NUC-7738 at the ESMO Immuno-Oncology Congress 2025, highlighting its effectiveness in treating PD-1 inhibitor-resistant metastatic melanoma [1][2][4] Clinical Data Summary - The combination of NUC-7738 and pembrolizumab showed clinical activity with two partial responses and seven cases of stable disease, including one case converting to a complete metabolic response [2][3] - A total of nine patients have been treated in the Expansion Cohort, with plans to enroll up to 28 additional patients, bringing the total to 40 [3] - No new safety signals were reported, and several patients continue to show ongoing disease control [3] Company Statements - The CEO of NuCana expressed satisfaction with the study's progress, emphasizing the potential benefits of NUC-7738 for patients with advanced melanoma [4] - The findings support continued enrollment and advancement towards a potential registrational pathway for NUC-7738 [4] Presentation Details - The presentation at the ESMO Congress included an abstract titled "A Phase 2 expansion study of NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant cutaneous melanoma" [5] - The poster number for the presentation was 321TiP, and it was presented by Dr. Miranda J. Payne [5] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology [6][7] - The company's pipeline includes NUC-7738, which targets multiple aspects of the tumor microenvironment, and NUC-3373, derived from the chemotherapy agent 5-fluorouracil [7]

Core Insights - NuCana plc announced promising data for its lead anti-cancer drugs NUC-7738 and NUC-3373, indicating potential for improved treatment outcomes for cancer patients [3] - The company is well-capitalized with cash reserves expected to last into 2029, following successful fundraising efforts [9][8] - Initial data from the expansion study of NUC-7738 is anticipated in Q4 2025, with final data expected in 2026 [1][6] Clinical Development Updates - NUC-7738 showed enhanced effectiveness when combined with PD-1 inhibitors, leading to increased tumor cell killing in a real-time organoid model [3] - The ongoing NuTide:701 study is recruiting additional patients with PD-1 inhibitor-resistant melanoma to explore optimal registration strategies [3] - NUC-3373 demonstrated durable activity in patients who had exhausted standard treatment options, with notable cases of significant tumor reduction [3] Financial Highlights - As of September 30, 2025, NuCana reported cash and cash equivalents of £25.2 million, a significant increase from £8.4 million in June 2025 [7] - The company reported a net loss of £0.3 million for Q3 2025, a decrease from a net loss of £4.5 million in Q3 2024 [10] - For the nine months ended September 30, 2025, the net loss was £26.9 million, compared to £18.3 million for the same period in 2024 [11] Anticipated Milestones - Initial data from the Phase 1/2 expansion study of NUC-7738 is expected in Q4 2025, with regulatory guidance from the FDA anticipated in 2026 [6] - Final data from the NuTide:701 study is also expected in 2026, alongside nonclinical data on NUC-3373's mode of action [6]

Core Insights - NuCana plc presented data at the European Society for Medical Oncology Congress 2025, demonstrating the synergistic effects of NUC-7738 in combination with PD-1 inhibitors in renal cell carcinoma [1][2] - The data reinforces the mechanism of action of NUC-7738, showing a favorable safety profile and significant tumor volume reduction in patients resistant to PD-1 inhibitors [3] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which transforms nucleoside analogs into more effective and safer medicines [5][6] - The company's pipeline includes NUC-7738, which disrupts RNA polyadenylation and targets multiple aspects of the tumor microenvironment, and NUC-3373, derived from 5-fluorouracil [6] Clinical Study Updates - The ongoing Phase 1/2 NuTide:701 clinical study is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab for melanoma patients, with an expansion to recruit an additional 28 patients approved by regulators [4][6] - Initial data from the NuTide:701 study indicates that NUC-7738 may sensitize various cancers to PD-1 inhibitor therapy, enhancing treatment options for patients [4][6]

Core Viewpoint - NuCana plc has confirmed compliance with Nasdaq's continued listing criteria, closing a previously disclosed listing matter, and is well-positioned for future operations and clinical milestones [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which enhances the efficacy and safety of widely prescribed chemotherapy agents [3]. - The company's pipeline includes NUC-7738, currently in Phase 2 trials for advanced solid tumors and melanoma, and NUC-3373, being evaluated in a Phase 1b/2 study for advanced solid tumors and lung cancer [3]. Financial Position - The company anticipates that its existing cash resources, bolstered by proceeds from an ATM offering, will be sufficient to fund operations into 2029 [2].

Core Points - NuCana plc will present at the ESMO Congress 2025, focusing on the synergy between NUC-7738 and PD-1 inhibition in renal cell cancer [1] - The presentation is scheduled for October 19, 2025, and will be part of the Investigational Immunotherapy session [1] - NuCana is a clinical-stage biopharmaceutical company utilizing ProTide technology to enhance chemotherapy agents [3] Company Overview - NuCana aims to improve cancer treatment outcomes by transforming nucleoside analogs into more effective and safer medicines [3] - The company's pipeline includes NUC-7738, which is in Phase 2 of a Phase 1/2 study, and NUC-3373, currently in a Phase 1b/2 modular study [3] - NUC-7738 targets multiple aspects of the tumor microenvironment and disrupts RNA polyadenylation [3]

Core Insights - NuCana plc has initiated the dosing of the first patients in the expansion study of NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant melanoma, with initial data expected in Q4 2025 and final data in 2026 [1][2] - The company reported a net loss of £24.1 million for Q2 2025, which includes a significant loss on revaluation of warrants, compared to a net loss of £7.0 million in Q2 2024 [7][11] - NuCana's cash and cash equivalents increased to £8.4 million as of June 30, 2025, up from £4.0 million at the end of Q1 2025, with additional funds raised through an ATM offering expected to extend the cash runway into 2029 [4][6] Clinical Development - NUC-7738 is designed to impact gene expression in cancer cells and has shown a favorable safety profile, meaningful tumor volume reduction, and prolonged progression-free survival in patients with PD-1 inhibitor refractory metastatic melanoma [2] - NUC-3373, another lead program, is a targeted thymidylate synthase inhibitor with immune-modulating properties, currently in a Phase 1b/2 study, showing notable tumor volume reductions and prolonged progression-free survival in patients with advanced solid tumors [2][5] Financial Position - As of June 30, 2025, NuCana's total assets were £16.2 million, with total equity attributable to equity holders amounting to £7.4 million [12][13] - The company has raised gross proceeds of £38.4 million in 2025 through various financing initiatives, positioning it well for upcoming clinical milestones [2][6] Anticipated Milestones - Initial data from the Phase 1/2 expansion study of NUC-7738 is expected in 2025, with regulatory guidance from the FDA anticipated in 2026 [5] - Additional data from the ongoing Phase 1b/2 study of NUC-3373 is also expected to be announced later in 2025 [5]

Core Viewpoint - NuCana plc has successfully canceled all remaining Series A Warrants, raising the necessary capital through its at-the-market offering, thereby eliminating overhanging rights from its May 2025 registered direct offering [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes using its ProTide technology to enhance the efficacy and safety of widely prescribed chemotherapy agents [3]. - The company's pipeline includes NUC-7738, a novel anti-cancer agent in Phase 2 studies, and NUC-3373, currently in a Phase 1b/2 modular study, both targeting advanced solid tumors [3].

Core Viewpoint - NuCana plc plans to change the ratio of its American Depository Shares (ADSs) from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares, effective around August 8, 2025, to support liquidity and regain compliance with Nasdaq's minimum bid price requirement [1][2]. Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which aims to enhance the efficacy and safety of widely prescribed chemotherapy agents [4]. - The company's pipeline includes NUC-7738, a novel anti-cancer agent in Phase 2 studies, and NUC-3373, currently in a Phase 1b/2 modular study, both targeting advanced solid tumors [4]. ADS Ratio Change Details - The change in the ADS Ratio will effectively act as a one-for-two hundred reverse ADS split, with no impact on the proportional equity interest of ADS holders [2]. - Registered holders of certificated ADSs must surrender their existing ADSs for cancellation to receive new ADSs, while holders of uncertificated ADSs will have their ADSs automatically exchanged [2]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [2]. Expected Impact - The trading price of ADSs is expected to increase proportionally due to the change in the ADS Ratio, although the company cannot guarantee that the new trading price will be equal to or greater than the previous price [3].

Core Insights - NuCana plc is advancing its clinical development programs for its lead anti-cancer medicines, NUC-7738 and NUC-3373, with a focus on key milestones towards commercialization [2][4][7] - The company has initiated an expansion study of NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant melanoma, with initial data expected in Q4 2025 and final data in 2026 [1][2] - Financial results for Q1 2025 show a net loss of £2.5 million, a significant reduction from £6.8 million in Q1 2024, indicating improved financial performance [6][10] Clinical Development Updates - NUC-7738 has shown a favorable safety profile and meaningful tumor volume reduction in patients with PD-1 inhibitor refractory metastatic melanoma, leading to the initiation of an expansion trial [2][4] - NUC-3373 is being evaluated in a Phase 1b/2 study in combination with pembrolizumab for advanced solid tumors and with docetaxel for lung cancer, with notable tumor volume reductions reported [2][4] - The company plans to meet with the U.S. FDA to discuss the regulatory strategy for NUC-7738 based on the promising results from ongoing studies [2][4] Financial Position - As of March 31, 2025, NuCana had cash and cash equivalents of £4.0 million, down from £6.7 million at the end of 2024, but has since raised an additional £8.8 million to extend its cash runway into Q4 2026 [4][5][6] - The company reported a basic and diluted loss per ordinary share of £0.02 for Q1 2025, compared to £0.13 for the same period in 2024, reflecting improved financial health [6][10] - Total assets decreased from £14.774 million at the end of 2024 to £11.601 million as of March 31, 2025, primarily due to cash outflows [11][12]